Incyte Secures FDA Approval for Jakafi XR™ (Ruxolitinib Extended-Release), Expanding Treatment Options for Patients with Blood Disorders and GVHD
Incyte has announced that the U.S. Food and Drug Administration has granted approval to Jakafi XR™ (ruxolitinib), a once-daily extended-release oral formulation, for the treatment of several serious hematologic conditions. These include adults diagnosed with intermediate- or high-risk Myelofibrosis (MF), adults with Polycythemia Vera (PV) who have shown inadequate response to or intolerance of hydroxyurea, and both adult and pediatric patients (aged 12 years and older) suffering from steroid-refractory acute or chronic Graft-versus-Host Disease (GVHD) after failure of prior systemic therapies.
This milestone marks an important advancement in treatment convenience and flexibility, as Jakafi XR introduces a once-daily dosing regimen compared to the traditional twice-daily immediate-release version of Jakafi.
A Step Forward in Patient-Centered Treatment
The approval of Jakafi XR underscores Incyte’s continued commitment to innovation in hematology and improving patient quality of life. By offering a simplified dosing schedule, the extended-release formulation addresses a significant challenge faced by patients managing chronic conditions—treatment adherence.
Bill Meury, Chief Executive Officer of Incyte, emphasized the importance of this advancement, noting that the approval strengthens the company’s leadership in hematologic therapies. He highlighted that Jakafi XR provides physicians and patients with an additional option without altering the established clinical role of ruxolitinib, which has been a cornerstone therapy for over a decade.
For patients managing complex conditions such as myeloproliferative neoplasms (MPNs) and GVHD, reducing dosing frequency can ease daily treatment burdens, improve adherence, and potentially enhance long-term outcomes.
Clinical Evidence Supporting Approval
The FDA’s decision was based on clinical data demonstrating that Jakafi XR achieves bioequivalence to the immediate-release formulation. Specifically, a once-daily 55 mg dose of Jakafi XR was shown to deliver comparable systemic exposure to a 25 mg immediate-release tablet taken twice daily.
This equivalence was established through pharmacokinetic measurements assessing drug concentration levels over time. The findings confirmed that Jakafi XR maintains consistent, therapeutic drug exposure throughout the day, ensuring similar efficacy potential to the established twice-daily regimen.
The ability to match the exposure profile of the original formulation while reducing dosing frequency is a significant achievement in drug formulation science, offering both clinical and lifestyle benefits.
Safety Profile and Adverse Effects
The safety of Jakafi XR is supported by extensive data derived from well-controlled clinical studies of the immediate-release formulation across approved indications. These studies included patients with myelofibrosis, polycythemia vera, and both acute and chronic GVHD.
Common adverse reactions observed include:
In Myelofibrosis and Polycythemia Vera:
- Low platelet counts (thrombocytopenia)
- Reduced red blood cell counts (anemia)
- Bruising
- Dizziness
- Headache
- Diarrhea
In Acute GVHD:
- Decreased platelet, red, or white blood cell counts
- Increased risk of infections
- Fluid retention and swelling
In Chronic GVHD:
- Anemia and thrombocytopenia
- Viral and other infections
These side effects are consistent with the known safety profile of ruxolitinib, and healthcare providers are already familiar with monitoring and managing them in clinical practice.
Expert Perspectives
Dr. Naveen Pemmaraju, a leukemia specialist at The University of Texas MD Anderson Cancer Center, emphasized the transformative impact of ruxolitinib since its initial approval in 2011. He noted that the introduction of Jakafi XR provides an important new option for patients who may benefit from a simplified dosing regimen.
According to Dr. Pemmaraju, patients with chronic hematologic conditions often face challenges such as multiple medications, complex schedules, and coexisting health issues. A once-daily therapy can significantly reduce this burden, making treatment more manageable and sustainable.
Researchers at MD Anderson have played a key role in the clinical development of ruxolitinib, contributing to its widespread adoption and success in treating MPNs and GVHD.
Improving Access Through Patient Support Programs
Incyte has also reinforced its commitment to patient access through its IncyteCARES program (Connecting to Access, Reimbursement, Education, and Support). This initiative provides eligible patients with comprehensive assistance, including:
- Financial support options
- Insurance navigation
- Educational resources
- Ongoing treatment support
Such programs are critical in ensuring that innovative therapies like Jakafi XR reach the patients who need them most, particularly in complex healthcare systems where cost and access can be barriers.
Understanding Myelofibrosis
Myelofibrosis is a rare and serious form of blood cancer classified under myeloproliferative neoplasms. It originates in the bone marrow, where abnormal stem cell activity leads to excessive production of blood cells and the formation of scar tissue.
This scarring disrupts normal blood cell production, resulting in symptoms such as:
- Severe anemia
- Chronic fatigue
- Weakness
- Enlarged spleen (splenomegaly)
- Enlarged liver
Myelofibrosis may develop independently or evolve from other MPNs, such as polycythemia vera or essential thrombocythemia. The disease can significantly impact quality of life and, in advanced stages, may progress to acute leukemia.
The Role of Ruxolitinib in Treatment
Ruxolitinib, the active ingredient in Jakafi XR, is a Janus kinase (JAK) inhibitor that targets key signaling pathways involved in abnormal blood cell production and inflammation.
By inhibiting JAK1 and JAK2 enzymes, ruxolitinib helps:
- Reduce spleen size
- Alleviate disease-related symptoms
- Improve overall quality of life
Its introduction revolutionized the treatment landscape for MPNs and GVHD, becoming a standard therapy in multiple indications.
Advantages of the Extended-Release Formulation
The development of Jakafi XR represents a meaningful innovation in drug delivery. Key benefits include:
1. Simplified Dosing
Patients can take the medication once daily instead of twice, improving convenience.
2. Consistent Drug Exposure
The extended-release mechanism ensures steady levels of medication throughout the day.
3. Potential for Better Adherence
Simpler regimens are associated with improved compliance, which can lead to better outcomes.
4. Flexibility in Treatment Planning
Physicians can tailor therapy based on patient preferences and lifestyle needs.
Availability and Market Introduction
Jakafi XR is expected to be available for pharmacy orders starting May 8, marking a rapid transition from approval to patient access. This swift rollout reflects both the urgency of patient need and the company’s readiness to deliver the therapy at scale.
Broader Impact on Hematology Care
The approval of Jakafi XR highlights a broader trend in oncology and hematology: the shift toward patient-centric treatment design. Beyond efficacy, factors such as convenience, quality of life, and adherence are increasingly recognized as critical components of successful therapy.
As more treatments evolve into extended-release or simplified regimens, patients can expect therapies that better align with their daily lives without compromising effectiveness.
The FDA approval of Jakafi XR marks a significant advancement in the management of myelofibrosis, polycythemia vera, and graft-versus-host disease. By combining proven efficacy with a more convenient once-daily dosing schedule, this extended-release formulation offers meaningful benefits for both patients and healthcare providers.
With strong clinical evidence, a well-established safety profile, and comprehensive patient support programs, Jakafi XR is poised to play an important role in the continued evolution of hematologic care.
About Polycythemia Vera
Polycythemia Vera (PV) is a part of a group of rare, chronic blood cancers called myeloproliferative neoplasms, or MPNs.3 PV occurs when bone marrow produces too many red blood cells, white blood cells and often platelets. Increased red blood cells and platelets can cause the blood to thicken, leading to an increased risk of blood clotting complications, including deep vein thrombosis, stroke or heart attack.4
Graft-versus-host disease (GVHD) is a condition that can occur after an allogeneic stem cell transplant (the transfer of stem cells from a donor) in which the donated cells initiate an immune response and attack the transplant recipient’s organs, leading to significant morbidity and mortality. There are two major forms of GVHD: acute, which generally occurs within 100 days of transplant, and chronic, which generally occurs after 100 days of transplant. Both forms can affect multiple organ systems, including the skin, gastrointestinal (digestive) tract and liver.5
